You are here

  • Home
  • Archive
  • Volume 11, Issue Suppl 1
  • 682 Trial in progress: phase 1 trial of TSC-100 and TSC-101, engineered T-cell therapies targeting minor histocompatibility antigens to eliminate residual disease after hematopoietic cell transplantation

Citation Tools

Article menu

Download PDFPDF

Regular and Young Investigator Award Abstracts
Clinical Trial In Progress
682 Trial in progress: phase 1 trial of TSC-100 and TSC-101, engineered T-cell therapies targeting minor histocompatibility antigens to eliminate residual disease after hematopoietic cell transplantation

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Malki MA, Keyzner A, Suh HC, et al
682 Trial in progress: phase 1 trial of TSC-100 and TSC-101, engineered T-cell therapies targeting minor histocompatibility antigens to eliminate residual disease after hematopoietic cell transplantation
Journal for ImmunoTherapy of Cancer 2023;11:doi: 10.1136/jitc-2023-SITC2023.0682